Remdesivir Announcement: As you may know, over the weekend, HHS announced the allocation plan for the drug remdesivir. Shipments are now going to the health departments in all 50 states, D.C., the territories, the Indian healthcare system, and the Veterans Health Administration.

The allocation is from a donation by Gilead Sciences, Inc. to the United States which was finalized on May 3, 2020. The donated doses of treatment, which received an Emergency Use Authorization (EUA) from the FDA, will be used to treat severely ill hospitalized COVID-19 patients. In total, the U.S. expects to receive 607,000 vials of the experimental drug over the coming weeks (enough to treat an estimated 78,000 COVID-19 patients).

As HHS receives product, we are shipping it to State Health Officers, expecting that the Governor, in consultation with the State Health Officer, will decide what hospitals receive the medication. We believe that state and local health departments have the greatest insight into community-level needs in the COVID-19 response, including appropriate distribution of a treatment in limited supply.


Click here to learn more.